We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Treatment and Outcome of Thrombolysis-Related Hemorrhage A Multicenter Retrospective Study

Shadi Yaghi, MD1,2; Amelia K. Boehme, MSPH, PhD1; Jamil Dibu, MD3; Christopher R. Leon Guerrero, MD4; Syed Ali, MD5; Sheryl Martin-Schild, MD, PhD6; Kara A. Sands, MD7; Ali Reza Noorian, MD8; Christina A. Blum, MD9; Shuchi Chaudhary, MD10; Lee H. Schwamm, MD11; David S. Liebeskind, MD8; Randolph S. Marshall, MD, MS1; Joshua Z. Willey, MD, MS1
[+] Author Affiliations
1Department of Neurology, Columbia University Medical Center, New York, New York
2currently with the Department of Neurology, Brown University, Providence, Rhode Island
3Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio
4Department of Neurology, Washington University in St Louis, St Louis, Missouri
5Department of Neurology, University of Arkansas for Medical Sciences, Fayetteville
6Department of Neurology, Tulane University, New Orleans, Louisiana
7Department of Neurology, The University of Alabama at Birmingham, Birmingham
8Department of Neurology, UCLA (University of California, Los Angeles), for the UCLA Acute Stroke Investigators, Los Angeles
9Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia
10Department of Neurology, University of Oklahoma, Norman
11Department of Neurology, Massachusetts General Hospital, Boston
JAMA Neurol. 2015;72(12):1451-1457. doi:10.1001/jamaneurol.2015.2371.
Text Size: A A A
Published online

Importance  Treatments for symptomatic intracerebral hemorrhage (sICH) are based on expert opinion, with limited data available on efficacy.

Objective  To better understand the natural history of thrombolysis-related sICH, with a focus on the efficacy of various treatments used.

Design, Setting, and Participants  Multicenter retrospective study between January 1, 2009, and April 30, 2014, at 10 primary and comprehensive stroke centers across the United States. Participants were all patients with sICH, using the definition by the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), which included a parenchymal hematoma type 2 and at least a 4-point increase in the National Institutes of Health Stroke Scale score.

Main Outcomes and Measures  The primary outcome was in-hospital mortality, and the secondary outcome was hematoma expansion, defined as a 33% increase in the hematoma volume on follow-up imaging.

Results  Of 3894 patients treated with intravenous recombinant tissue plasminogen activator (rtPA) within 4½ hours after symptom onset of ischemic stroke, 128 (3.3%) had sICH. The median time from initiation of rtPA therapy to sICH diagnosis was 470 minutes (range, 30-2572 minutes), and the median time from diagnosis to treatment of sICH was 112 minutes (range, 12-628 minutes). The in-hospital mortality rate was 52.3% (67 of 128), and 26.8% (22 of 82) had hematoma expansion. In the multivariable models, code status change to comfort measures after sICH diagnosis was the sole factor associated with increased in-hospital mortality (odds ratio, 3.6; 95% CI, 1.2-10.6). Severe hypofibrinogenemia (fibrinogen level, <150 mg/dL) was associated with hematoma expansion, occurring in 36.3% (8 of 22) of patients without hematoma expansion vs in 25.0% (15 of 60) of patients with hematoma expansion (P = .01), highlighting a role for cryoprecipitate in reversing rtPA coagulopathy.

Conclusions and Relevance  In this study, treatment of postthrombolysis sICH did not significantly reduce the likelihood of in-hospital mortality or hematoma expansion. Shortening the time to diagnosis and treatment may be a key variable in improving outcomes of patients with sICH.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1.
Patient Flowchart

rtPA indicates recombinant tissue plasminogen activator; sICH, symptomatic intracerebral hemorrhage; and SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Patient With Thrombolysis-Related Symptomatic Intracerebral Hemorrhage

Hematoma expansion was noted on follow-up imaging despite treatment with cryoprecipitate.

Graphic Jump Location





You need to register in order to view this quiz.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Three Fundamental Principles of EBM

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Best Evidence Summaries